Company Monitoring Page for Roche

latest headlines for company on cafepharma

Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche
Fierce Pharma
Wed, 04/24/24 - 08:50 am
Tags:
orphan drugs, Evaluate Pharma, JNJ, Vertex Pharmaceuticals, Roche
Roche wins FDA OK for targeted drug in early lung cancer
BioPharma Dive
Fri, 04/19/24 - 11:40 am
Tags:
Roche, Alecensa, ALK inhibitors, FDA, non-small cell lung cancer
Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation
Xtalks
Thu, 04/18/24 - 10:28 pm
Tags:
Roche, FDA, Medtech, Eli Lilly, Elecsys pTau217, Alzheimer's disease, diagnostics
Roche touts near-complete suppression of multiple sclerosis relapse for injectable Ocrevus
Fierce Pharma
Wed, 04/17/24 - 11:33 am
Tags:
Roche, Ocrevus, MS, multiple sclerosis, AAN
Pfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures
Fierce Biotech
Wed, 04/17/24 - 11:20 am
Tags:
Pfizer, R&D, Roche
Roche’s Columvi offers survival benefit in Phase III DLBCL trial
Clinical Trials Arena
Mon, 04/15/24 - 11:07 am
Tags:
Roche, clinical trials, Columvi, DLBCL
Roche, Adaptimmune part ways on cell therapy research
BioPharma Dive
Sun, 04/14/24 - 01:26 pm
Tags:
Roche, Genentech, cell therapy, cancer, Adaptimmune
FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test
Pharmaphorum
Thu, 04/11/24 - 10:52 am
Tags:
diagnostics, Roche, Eli Lilly, Alzheimer's disease, FDA, breakthrough designation
5 Successful Phase III Oncology Trials in Q1
BioSpace
Tue, 04/9/24 - 11:50 am
Tags:
oncology, clinical trials, Bristol Myers Squibb, Opdivo, Yervoy, liver cancer, Pfizer, DLBCL, Adcetris, Asieris, HSIL, APL-1702, cervical cancer, Novocure, non-small cell lung cancer, Roche, Genentech, Tecentriq, esophageal squamous cell carcinoma
Roche autoimmune disease drug disappoints in closely watched trial
BioPharma Dive
Thu, 03/21/24 - 06:36 pm
Tags:
Roche, Chugai, clinical trials, myasthenia gravis, Enspryng
Pfizer's Braftovi to command 42% share of BRAF inhibitors melanoma market by 2028
Biopharma Reporter
Thu, 03/21/24 - 11:37 am
Tags:
Pfizer, Braftovi, Roche, Zelboraf, melanoma
BMS racks up phase III win in liver cancer targeted by AstraZeneca and Roche
BioSpace
Wed, 03/20/24 - 11:51 am
Tags:
Bristol Myers Squibb, immuno-oncology, Opdivo, Yervoy, liver cancer, AstraZeneca, Roche
Lonza adds biologics capacity with $1.2bn Roche deal
Pharmaphorum
Wed, 03/20/24 - 11:17 am
Tags:
Roche, Lonza, drug manufacturing, Switzerland, CDMOs
Roche Plots Neuro Comeback with Promising Mid-Stage Alzheimer’s Data
BioSpace
Tue, 03/12/24 - 11:14 am
Tags:
Roche, Alzheimer's disease, monoclonal antibodies
Roche to take on Abbott, Dexcom with its first CGM
Medtech Dive
Fri, 03/8/24 - 11:13 am
Tags:
Medtech, Roche, CGMs, diabetes, Abbott Labs, DexCom, Accu-Chek Smartguide
Asthma Drug Xolair Now Indicated For Food Allergies: Next Challenge Is Insurer Coverage
Forbes
Wed, 03/6/24 - 11:25 am
Tags:
Roche, Novartis, Xolair, insurers, food allergies
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
Reuters
Tue, 03/5/24 - 11:07 am
Tags:
Roche, Alnylam Pharmaceuticals, clinical trials, hypertension, zilebesiran
Roche Reassesses Esbriet's Future Amidst Generic Drug Competition
Medriva
Tue, 02/27/24 - 11:28 am
Tags:
Roche, generics, Esbriet, IPF
Roche evaluates options for its lung disease drug
Reuters
Mon, 02/26/24 - 05:12 pm
Tags:
Roche, Esbriet, lung cancer
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
Tags:
oncology, clinical trials, Daiichi Sankyo, AstraZeneca, Enhertu, metastatic breast cancer, Gilead Sciences, Trodelvy, bladder cancer, GSK, Zejula, Jemperli, ovarian cancer, Roche, tiragolumab, Tecentriq, non-small cell lung cancer, Cue Biopharma, CUE-101, head and neck cancer, Elicio Therapeutics, ELI-002, solid tumors

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.